LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Stock List・Sana Biotechnology Inc

Sana Biotechnology Inc

Closed

SectorHealthcare

3.05 0.33

Buy Sell

Overview

Share price change

24h

Current

Min

3.01

Max

3.22

Key metrics
By Trading Economics
Income	12M -47M
EPS	-0.171
Employees	142
EBITDA	23M -35M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+184.59% upside

Dividends
By Dow Jones
Next Earnings	7 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-107M 854M
Previous open	2.72
Previous close	3.05

News Sentiment

By Acuity

25%

75%

39 / 344 Healthcare

Sana Biotechnology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 May 2026, 21:33 UTC

Earnings

Correction to Salesforce 1Q Sales, Profit Rise Article

27 May 2026, 21:00 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 May 2026, 20:18 UTC

Earnings

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 May 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 May 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 May 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 May 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27 May 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 May 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 May 2026, 21:29 UTC

Hot Stocks

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 May 2026, 21:08 UTC

Earnings

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 May 2026, 21:02 UTC

Earnings

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 May 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 May 2026, 20:55 UTC

Earnings

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 May 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 May 2026, 20:48 UTC

Earnings

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 May 2026, 20:45 UTC

Earnings

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 May 2026, 20:34 UTC

Acquisitions, Mergers, Takeovers

Webster Financial Stockholders Approve Sale to Banco Santander

27 May 2026, 20:32 UTC

Earnings

Acquisitions, Mergers, Takeovers

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 May 2026, 20:32 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 May 2026, 20:32 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 May 2026, 20:30 UTC

Earnings

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 May 2026, 20:30 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 May 2026, 20:22 UTC

Earnings

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 May 2026, 20:16 UTC

Earnings

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 May 2026, 20:13 UTC

Earnings

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 May 2026, 20:13 UTC

Earnings

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 May 2026, 20:13 UTC

Earnings

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 May 2026, 20:12 UTC

Earnings

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 May 2026, 20:12 UTC

Earnings

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Peer Comparison

Price change

Sana Biotechnology Inc Forecast

Price Target

By TipRanks

184.59% upside

12 Months Forecast

Average 8.68 USD 184.59%

High 16 USD

Low 3.07 USD

Based on 7 Wall Street analysts offering 12 month price targets forSana Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Sana Biotechnology Inc - Dist in the past 3 months.

Sentiment

By Acuity

39 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.